Literature DB >> 1365867

Performance of baboons under a repeated acquisition procedure during chronic oral exposure to atenolol and propranolol.

J S Turkkan1, R D Hienz.   

Abstract

Repeated acquisition behavioral performances of normotensive and renovascular hypertensive baboons were tested before, during, and following chronic oral dosing with the beta-adrenergic antagonists atenolol HCl (2.6 mg/kg/day PO), and d,l propranolol HCl (6.8 mg/kg twice daily PO) in separate studies. Each study administered active drug for 21 consecutive days preceded and followed by 14-day baseline and recovery periods, respectively. Animals pressed five keys in sequence for food reinforcement during daily experimental sessions which consisted of alternating acquisition (new sequence learning) and performance (previously learned) task components. Atenolol increased response latencies during acquisition in comparison to performance components, and during early portions of sessions. Propranolol also increased response latencies during acquisition components in early periods of sessions, but fewer dependent measures were affected, and the magnitude of increases in response latencies was smaller (12% +/- 5 SEM) as compared with atenolol (47% +/- 13). Test doses of phencyclidine HCl (PCP) increased latencies to the same degree as atenolol. PCP markedly reduced accuracy, while atenolol or propranolol did not. Blood pressures remained stable under atenolol, and decreased by approximately 10-15 mmHg under propranolol. No differences between renovascular hypertensive and normotensive baboons were found as a function of drug conditions. Drug effects were not dependent on plasma propranolol concentration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365867     DOI: 10.1007/bf02247728

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  New methodology for measuring blood pressure in awake baboons with use of behavioral training techniques.

Authors:  J S Turkkan
Journal:  J Med Primatol       Date:  1990       Impact factor: 0.667

2.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

Review 3.  Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Drugs       Date:  1974       Impact factor: 9.546

4.  Effects of two forms of hypertension on atherosclerosis in the hyperlipidemic baboon.

Authors:  H C McGill; K D Carey; C A McMahan; Y N Marinez; T E Cooper; G E Mott; C J Schwartz
Journal:  Arteriosclerosis       Date:  1985 Sep-Oct

5.  Effects of anticonvulsants on learning: performance of pigeons under a repeated acquisition procedure when exposed to phenobarbital, clonazepam, valproic acid, ethosuximide and phenytoin.

Authors:  M Picker; A Poling
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

6.  Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect.

Authors:  F M Gengo; L Huntoon; W B McHugh
Journal:  Arch Intern Med       Date:  1987-01

7.  Central effects of beta-adrenoceptor antagonists.

Authors:  S A Salem; D G McDevitt
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

8.  Production and reversal of DOCA-salt hypertension in baboons.

Authors:  J S Turkkan; D S Goldstein
Journal:  Clin Exp Hypertens A       Date:  1987

9.  Effects of phencyclidine, pentobarbital, and d-amphetamine on the acquisition and performance of conditional discriminations in monkeys.

Authors:  J M Moerschbaecher; D M Thompson
Journal:  Pharmacol Biochem Behav       Date:  1980-12       Impact factor: 3.533

Review 10.  Side effects of beta-blocker treatments as related to the central nervous system.

Authors:  C Dahlöf; E Dimenäs
Journal:  Am J Med Sci       Date:  1990-04       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.